MHRA consults on bespoke regulation of ‘point of care’ products

Personalised treatments manufactured at the point of care in the UK, including cell and gene therapies, would be subject to a bespoke new regulatory framework under plans being developed by the Medicines and Healthcare products Regulatory Agency (MHRA).

Read Complete Article

MITLA is a member of the INPLP

    Subscribe for the latest
    IT Law updates

    Receive the latest IT Law updates straight to your inbox, gain access to our exclusive industry events, keep up to date with MITLA.